Table 2 Basic characteristics of included studies for plasma ptau181 analysis

Suárez-Calvet et al. (2020) [84]

CN (250)

38

60.6 ± 4.44

8.83 ± 3.21

1

Simoa - Karikari method

Moscoso et al. (2021) [85]

CN (374)

47.1

74.8 ± 6.6

13.3 ± 10.7

1

Simoa - Karikari method

O’Connor et al. (2020) [86]

CN (27)

41

38.1 ± 10.7

9.7 ± 9.3

1, 2 and 3

Simoa - Karikari method

AD (19)

63

50.7 ± 10.0

23.7 ± 10.5

Rodriguez et al. (2020) [87]

CN (28)

35.7

82.2 ± 6.5

19.3 ± 9.9

1, 2 and 3

Simoa - Karikari method

AD (77)

46.1

81.7 ± 7.6

28.4 ± 9.6

Karikari et al. (2020) - TRIAD cohort [88]

CN-young (27)

37

22.7 ± 1.9

7.9 ± 2.6

1, 2 and 3

Simoa - Karikari method

CN-old (113)

36

69.2 ± 9.7

10 ± 3.3

AD (33)

55

64.6 ± 9.2

24.9 ± 7.8

Karikari et al. (2020) -BioFINDER-2 cohort [88]

CN-old (337)

46

63.1 ± 5.0

9.4 ± 6.0

1, 2 and 3

Simoa - Karikari method

AD (126)

47

74.0 ± 6.9

19.2 ± 9.4

Karikari et al. (2020) [45]

CN (268)

51.1

73.5 ± 6.5

14.2 ± 9.0

1, 2 and 3

Simoa - Karikari method

AD (137)

52.2

73.4 ± 8.2

25.8 ± 8.6

Mielke et al. (2018) [60]

CN (172)

69.2

71.9 ± 9.5

6.4 ± 6.4

1, 2 and 3

MSD

AD (40)

23

67.7 ± 9.2

11.6 ± 4.1

Thijssen et al. (2020) [89]

CN (69)

53.6

60.8 ± 22

2.4 ± 3

1, 2 and 3

MSD

AD (56)

41.1

65 ± 9

8.4 ± 4

Janelidze et al. (2020) - Cohort1 [90]

CN (26)

38.5

74 ± 5.2

1.3 ± 1.1

1, 2 and 3

MSD

AD (38)

44.7

73 ± 8.1

4.4 ± 2.3

Janelidze et al. (2020) - Cohort2 [90]

CN (126)

61.9

71 ± 5.2

1.2 ± 0.59

1, 2 and 3

MSD

AD (81)

43.2

73 ± 5.2

2.8 ± 2.07

Janelidze et al. (2020) – Cohort3 [90]

CN (47)

59.6

83 ± 9.6

1.8 ± 1.04

1, 2 and 3

MSD

AD (16)

75.0

83 ± 7.4

4 ± 2.07